Cardionet Inc - Statement of Changes in Beneficial Ownership (4)

Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

Get Started

Cardionet Inc - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2008 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Sanderling Venture Partners IV, L.P.	2. Issuer Name and Ticker or Trading Symbol CARDIONET INC [ BEAT ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) 400 SOUTH EL CAMINO REAL, SUITE 1200	3. Date of Earliest Transaction (MM/DD/YYYY) 3/25/2008
(Street) SAN MATEO, CA 94402 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	3/25/2008		C		26860	A	⁽¹⁾	26860	I	See Footnote ⁽²⁾
Common Stock	3/25/2008		C		5640	A	⁽³⁾	32501	I	See Footnote ⁽²⁾
Common Stock	3/25/2008		C		8506 ⁽¹⁰⁾	A	$3.50	41007	I	See Footnote ⁽²⁾
Common Stock	3/25/2008		C		11370	A	⁽⁴⁾	52377	I	See Footnote ⁽²⁾
Common Stock	3/25/2008		C		111919	A	⁽¹⁾	111919	I	See Footnote ⁽⁵⁾
Common Stock	3/25/2008		C		23503	A	⁽³⁾	135422	I	See Footnote ⁽⁵⁾
Common Stock	3/25/2008		C		35449 ⁽¹⁰⁾	A	$3.50	170871	I	See Footnote ⁽⁵⁾
Common Stock	3/25/2008		C		47287	A	⁽⁴⁾	218158	I	See Footnote ⁽⁵⁾
Common Stock	3/25/2008		C		30187	A	⁽¹⁾	30187	I	See Footnote ⁽⁶⁾
Common Stock	3/25/2008		C		6339	A	⁽³⁾	36526	I	See Footnote ⁽⁶⁾
Common Stock	3/25/2008		C		9560 ⁽¹⁰⁾	A	$3.50	46086	I	See Footnote ⁽⁶⁾
Common Stock	3/25/2008		C		12774	A	⁽⁴⁾	58860	I	See Footnote ⁽⁶⁾
Common Stock	3/25/2008		C		184604	A	⁽¹⁾	184604	I	See Footnote ⁽⁷⁾
Common Stock	3/25/2008		C		38767	A	⁽³⁾	223371	I	See Footnote ⁽⁷⁾
Common Stock	3/25/2008		C		58472 ⁽¹⁰⁾	A	$3.50	281843	I	See Footnote ⁽⁷⁾
Common Stock	3/25/2008		C		77920	A	⁽⁴⁾	359763	I	See Footnote ⁽⁷⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series C Convertible Preferred Stock	⁽¹⁾	3/25/2008		C			53721	⁽¹⁾	⁽¹⁾	Common Stock	26860	$0	0	I	See Footnote ⁽²⁾
Series D Convertible Preferred Stock	⁽³⁾	3/25/2008		C			11281	⁽³⁾	⁽³⁾	Common Stock	5640	$0	0	I	See Footnote ⁽²⁾
Warrants to Purchase Series D-1 Convertible Preferred Stock	$3.50	3/25/2008		C			27844	⁽⁸⁾	⁽⁹⁾	Common Stock	8506 ⁽¹⁰⁾	$0	0	I	See Footnote ⁽²⁾
Mandatorily Convertible Preferred Stock	⁽⁴⁾	3/25/2008		C			170	⁽⁴⁾	⁽⁴⁾	Common Stock	11370	$0	0	I	See Footnote ⁽²⁾
Series C Convertible Preferred Stock	⁽¹⁾	3/25/2008		C			223839	⁽¹⁾	⁽¹⁾	Common Stock	111919	$0	0	I	See Footnote ⁽⁵⁾
Series D Convertible Preferred Stock	⁽³⁾	3/25/2008		C			47006	⁽³⁾	⁽³⁾	Common Stock	23503	$0	0	I	See Footnote ⁽⁵⁾
Warrants to Purchase Series D-1 Convertible Preferred Stock	$3.50	3/25/2008		C			116019	⁽⁸⁾	⁽⁹⁾	Common Stock	35449 ⁽¹⁰⁾	$0	0	I	See Footnote ⁽⁵⁾
Mandatorily Convertible Preferred Stock	⁽⁴⁾	3/25/2008		C			707	⁽⁴⁾	⁽⁴⁾	Common Stock	47287	$0	0	I	See Footnote ⁽⁵⁾
Series C Convertible Preferred Stock	⁽¹⁾	3/25/2008		C			60374	⁽¹⁾	⁽¹⁾	Common Stock	30187	$0	0	I	See Footnote ⁽⁶⁾
Series D Convertible Preferred Stock	⁽³⁾	3/25/2008		C			12679	⁽³⁾	⁽³⁾	Common Stock	6339	$0	0	I	See Footnote ⁽⁶⁾
Warrants to Purchase Series D-1 Convertible Preferred Stock	$3.50	3/25/2008		C			31293	⁽⁸⁾	⁽⁹⁾	Common Stock	9560 ⁽¹⁰⁾	$0	0	I	See Footnote ⁽⁶⁾
Mandatorily Convertible Preferred Stock	⁽⁴⁾	3/25/2008		C			191	⁽⁴⁾	⁽⁴⁾	Common Stock	12774	$0	0	I	See Footnote ⁽⁶⁾
Series C Convertible Preferred Stock	⁽¹⁾	3/25/2008		C			369209	⁽¹⁾	⁽¹⁾	Common Stock	184604	$0	0	I	See Footnote ⁽⁷⁾
Series D Convertible Preferred Stock	⁽³⁾	3/25/2008		C			77534	⁽³⁾	⁽³⁾	Common Stock	38767	$0	0	I	See Footnote ⁽⁷⁾
Warrants to Purchase Series D-1 Convertible Preferred Stock	$3.50	3/25/2008		C			191369	⁽⁸⁾	⁽⁹⁾	Common Stock	58472 ⁽¹⁰⁾	$0	0	I	See Footnote ⁽⁷⁾
Mandatorily Convertible Preferred Stock	⁽⁴⁾	3/25/2008		C			1165	⁽⁴⁾	⁽⁴⁾	Common Stock	77920	$0	0	I	See Footnote ⁽⁷⁾

Explanation of Responses:
( 1)	Each 2 shares of Series C Convertible Preferred Stock converted into 1 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
( 2)	By Sanderling V Beteilingungs GmbH & Co KG. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Beteilingungs GmbH & Co KG and has voting and investment power over the shares held by Sanderling V Beteilingungs GmbH & Co KG. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 3)	Each 2 shares of Series D Convertible Preferred Stock converted into 1 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
( 4)	Each share of Mandatorily Convertible Preferred Stock converted into 66.88 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
( 5)	By Sanderling V Biomedical Co-Investment Fund L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Biomedical Co-Investment Fund L.P and has voting and investment power over the shares held by Sanderling V Biomedical Co-Investment Fund L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 6)	By Sanderling V Limited Partnership. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Limited Partnership and has voting and investment power over the shares held by Sanderling V Limited Partnership. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 7)	By Sanderling Venture Partners V Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling Venture Partners V Co-Investment Fund, L.P and has voting and investment power over the shares held by Sanderling Venture Partners V Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 8)	Warrants became exercisable on March 8, 2007.
( 9)	Warrants to purchase Series D-1 Convertible Preferred were automatically net exercised immediately prior to the closing of the Issuer's initial public offering. Each 2 shares of Series D-1 Convertible Preferred Stock converted into 1 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
( 10)	Warrants were net exercised resulting in fewer shares being issued than if the exercise price had been paid for with cash.

Remarks:
Exhibit 24.1 Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Sanderling Venture Partners IV, L.P. 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402		X
SANDERLING V BETEILIGUNGS GMBH & CO KG 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402		X
SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402		X
Sanderling Venture Partners V Co Investment Fund, LP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402		X
SANDERLING V LTD PARTNERSHIP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402		X

Signatures
See Ex. 99.1		3/26/2008
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more HeartBeam Charts.

HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more HeartBeam Charts.

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Share on Facebook Share on Twitter Share on Email

Loading Messages....

See More Message Board Posts

Cardionet Inc News

More Cardionet Inc News Articles

Code Green Apparel (PK)

Ethema Health (PK)

Movement Industries (PK)

Kraig Biocraft Laborator... (QB)

Digital Brand Media and ... (PK)

Northwest Biotherapeutics (QB)

Fannie Mae (QB)

Anavex Life Sciences

Elite Pharmaceuticals (QB)

Intergrated Cannabis Sol... (PK)

Rennova Health (PK)

NioCorp Developments

RespireRx Pharmaceuticals (PK)

Delayed Upgrade Clock